Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$1.62 -0.9%	$1.07	$0.65 ▼ $26.25	$17.01M	1.23	777,080 shs	91,572 shs
EYEG AB Corporate Bond ETF	$35.42 +1.9%	$1.90	$33.92 ▼ $37.24	$25.89M	0.16	1,370 shs	2,893 shs
SEOVF Sernova Biotherapeutics	$0.12 -0.3%	$0.13	$0.10 ▼ $0.25	$38.70M	1	32,194 shs	8,000 shs
SXTC China SXT Pharmaceuticals	$1.67 -2.3%	$1.74	$0.95 ▼ $11.92	$195.51M	1.18	1.19 million shs	1,600 shs
TLGT Teligent		$0.03	$0.17 ▼ $1.60	N/A	N/A	N/A	6,460 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	-7.91%	-25.74%	+53.77%	+73.40%	-91.26%
EYEG AB Corporate Bond ETF	+0.21%	-0.21%	+1.09%	+2.98%	-0.51%
SEOVF Sernova Biotherapeutics	-0.34%	+8.27%	-3.60%	-6.58%	-43.90%
SXTC China SXT Pharmaceuticals	-3.39%	-6.30%	-18.96%	-31.33%	-80.02%
TLGT Teligent	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTXR Citius Pharmaceuticals	2.4932 of 5 stars	3.4	2.0	0.0	0.0	2.0	0.8	1.3
EYEG AB Corporate Bond ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.1608 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.0	0.6
TLGT Teligent	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.80	Moderate Buy	$53.00	3,181.73% Upside
EYEG AB Corporate Bond ETF	0.00	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	0.00	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
TLGT Teligent	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SXTC, SEOVF, EYEG, TLGT, and CTXR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/9/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/23/2025	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	CTXR Citius Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$10.25 per share	N/A
EYEG AB Corporate Bond ETF	$10K	2,656.13	N/A	N/A	$1.26 per share	28.11
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	($0.03) per share	N/A
SXTC China SXT Pharmaceuticals	$1.93M	100.40	N/A	N/A	$243.66 per share	0.01
TLGT Teligent	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	1.29	N/A	N/A	-58.63%	-37.67%	8/11/2025 (Estimated)
EYEG AB Corporate Bond ETF	-$8.09M	-$1.68	N/A	N/A	N/A	N/A	-104.96%	-60.03%	N/A
SEOVF Sernova Biotherapeutics	-$23.65M	-$0.04	N/A	∞	N/A	N/A	N/A	-396.49%	9/15/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TLGT Teligent	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest SXTC, SEOVF, EYEG, TLGT, and CTXR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
6/13/2025	Q2 2025	SEOVF Sernova Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/14/2025	Q2 2025	CTXR Citius Pharmaceuticals	-$1.08	-$1.27	-$0.19	-$1.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EYEG AB Corporate Bond ETF	$2.10	5.93%	N/A	N/A	N/A
SEOVF Sernova Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLGT Teligent	N/A	N/A	N/A	N/A	N/A

Latest SXTC, SEOVF, EYEG, TLGT, and CTXR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/30/2025	EYEG AB Corporate Bond ETF	Monthly	$0.1423	4.81%	7/1/2025	7/1/2025	7/7/2025
5/30/2025	EYEG AB Corporate Bond ETF	Monthly	$0.1507	5.19%	6/2/2025	6/2/2025	6/5/2025
4/30/2025	EYEG AB Corporate Bond ETF		$0.1501		5/1/2025	5/1/2025	5/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	N/A	0.37	0.06
EYEG AB Corporate Bond ETF	0.01	3.07	3.07
SEOVF Sernova Biotherapeutics	N/A	0.12	0.12
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
TLGT Teligent	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
EYEG AB Corporate Bond ETF	64.16%
SEOVF Sernova Biotherapeutics	N/A
SXTC China SXT Pharmaceuticals	5.02%
TLGT Teligent	N/A

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	10.70%
EYEG AB Corporate Bond ETF	58.20%
SEOVF Sernova Biotherapeutics	N/A
SXTC China SXT Pharmaceuticals	3.95%
TLGT Teligent	0.17%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	10.63 million	9.50 million	Optionable
EYEG AB Corporate Bond ETF	14	750,000	5.28 million	Not Optionable
SEOVF Sernova Biotherapeutics	N/A	328.48 million	N/A	Not Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
TLGT Teligent	2,357	N/A	N/A	Optionable

SXTC, SEOVF, EYEG, TLGT, and CTXR Headlines

Recent News About These Companies

PAC Profile: Teligent

September 11, 2024 | opensecrets.orgO

Topical pain reliever recalled for problem that can cause ‘severe morbidity, even death’

June 7, 2023 | charlotteobserver.comC

β1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzz

May 13, 2023 | news.google.comN

Lidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan News

May 13, 2023 | news.google.comN

Global Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Today

May 11, 2023 | news.google.comN

Global Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examiner

May 8, 2023 | news.google.comN

Dry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPR

May 8, 2023 | news.google.comN

Mobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journal

May 8, 2023 | news.google.comN

Mobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examiner

May 5, 2023 | news.google.comN

Epinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journal

May 3, 2023 | news.google.comN

Erythromycin Market with Focus on Growth Analysis, Production ... - Digital Journal

May 2, 2023 | news.google.comN

From 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journal

April 29, 2023 | news.google.comN

Tremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPR

April 28, 2023 | news.google.comN

Drugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPR

April 26, 2023 | news.google.comN

Topical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPR

April 26, 2023 | news.google.comN

Triamcinolone Market | Driving Factors, Industry Analysis ... - Taiwan News

April 24, 2023 | news.google.comN

IDT Corp. Cl B

April 23, 2023 | wsj.com

Mobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journal

April 17, 2023 | news.google.comN

Hikma Names Injectables Chief Mishlawi As CEO - Generics Bulletin

April 12, 2023 | news.google.comN

Mobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journal

April 10, 2023 | news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, SEOVF, EYEG, TLGT, and CTXR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$1.62 -0.02 (-0.92%)

As of 10:32 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

AB Corporate Bond ETF NASDAQ:EYEG

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

Sernova Biotherapeutics OTCMKTS:SEOVF

$0.12 0.00 (-0.34%)

As of 10:07 AM Eastern

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs. Sernova Corp. has a research agreement with the University of Miami to advance the development of Conformal Coating Technology in combination with therapeutic cells within Cell Pouch. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.67 -0.04 (-2.34%)

As of 10:30 AM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Teligent NASDAQ:TLGT

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time